Nippon India Pharma Fund

A Sectoral/Thematic Fund scheme from Nippon India Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF204K01I50).

NAV ₹659.3613 on 16 November 2026.

Expense ratio

Total expense ratio 0.99% a year for the Direct · Growth plan, as AMFI published it on 29 October 2026: base expense ratio 0.79%, brokerage 0.02%, transaction costs 0.00%, statutory levies including GST 0.18%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year13.4%12.8%-9.6%0.500.54
3 years18.4%13.2%-14.7%0.870.86
5 years14.8%13.1%-18.7%0.600.60
10 years16.6%15.6%-21.2%0.610.62

Category rank: 12th of 13 Direct-Growth funds in Sectoral/Thematic Fund — Pharma, by 3-year Sortino ratio.

Largest holdings

Top 10 (October 2026 disclosure). Company shares make up 99.6% of the portfolio.

  1. Sun Pharmaceutical Industries Limited — 11.55%
  2. Divi's Laboratories Limited — 6.73%
  3. Cipla Limited — 6.21%
  4. Lupin Limited — 6.16%
  5. Dr. Reddy's Laboratories Limited — 6.13%
  6. Apollo Hospitals Enterprise Limited — 5.10%
  7. Mankind Pharma Limited — 4.40%
  8. Sai Life Sciences Limited — 4.04%
  9. Ajanta Pharma Limited — 3.53%
  10. Max Healthcare Institute Limited — 3.31%

Plans

Other funds in Sectoral/Thematic Fund

All 257 funds in Sectoral/Thematic Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.